American Association for Cancer Research
- AbstractPatients with pancreatic ductal adenocarcinoma (PDAC) harboring KRASG12R mutations have increased overall survival relative to patients with KRASG12D/V mutations. To investigate the mechanisms underlying this differential outcome, we developed a genetically engineered mouse model (GEMM) harboring KrasG12R and Trp53R172H mutations (KrasLSL-G12R/+;Trp53LSL-R172H/+;p48Cre-ERTM). Unlike KrasG12D models, KrasG12R GEMMs exhibited limited tumorigenesis, with only 10% developing pancreatic tumors […]
- AbstractThe immunosuppressive tumor microenvironment (TME) enables cancer cells to evade clinical immunotherapies. Neural networks are vital components of the TME, and interactions among cancer cells, neuronal cells, and immune cells mediate immunosuppression. Hence, understanding the mechanisms of intercellular cross-talk could inform immunomodulatory approaches to enhance immunotherapy efficacy. In this study, we found that the vagus […]
- AbstractPancreatic ductal adenocarcinoma (PDAC) is defined by the near universal occurrence of KRAS mutations. The KRASG12R mutation is detected in approximately 15% to 20% of patients with PDAC and rare in other KRAS-mutant cancers. KRASG12R is unable to activate the lipid kinase PIK3CA, suggesting that alternative mechanisms might be employed to activate KRASG12R-independent PI3K signaling […]
- AbstractTherapies targeting the RAF–MEK–ERK pathway are generally considered to have limited efficacy in KRAS-mutant cancers. However, specific KRAS mutants exhibit distinct behaviors. Notably, KRASG12R pancreatic ductal adenocarcinoma (PDAC) tumors have shown sensitivity to MEK inhibitors (MEKi) in combination with autophagy inhibitors, but a better understanding of the underlying mechanisms is needed to optimize this treatment […]
- AbstractLocalized prostate cancers are heterogeneous and multifocal, with diverse outcomes. Current prognostic methods are epithelium-centric, overlooking the complex cellular landscape within the tumor microenvironment (TME). To further characterize the heterogeneity of the TME, we performed a comprehensive analysis of cancerous and adjacent-benign cores from 24 patients with hormone therapy–naïve localized prostate cancer using single-cell RNA […]
- AbstractOncogenic RAS drives an immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC). Inhibition of RAS signaling, as is now possible with an ever-increasing pharmaceutical portfolio, not only directly blocks tumor cells but also reverses immunosuppression, enabling infiltration of cytotoxic T cells and major alteration of the tumor microenvironment. In preclinical studies, the full antitumor effects […]
- AbstractPurpose:Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-[DOTA0,Tyr3]octreotate (177Lu-Dotatate) is an effective and safe treatment for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP NET). Whereas 177Lu-Dotatate prolongs progression-free survival (PFS) and preserves quality of life (QoL), objective response rates (ORR) remain limited. Capecitabine, as a radiosensitizer, could increase efficacy without increasing 177Lu-Dotatate activity. This phase II […]
- AbstractMost patients with solid tumors either never benefit from immune checkpoint inhibitors (ICI) or relapse after an initial response, underscoring the need for additional therapies. Clinical and translational evidence points to two complementary strategies to overcome ICI resistance: redirection of effector cells by imposing novel tumor specificity via engineered T-cell receptors (TCR), chimeric antigen receptors […]
- AbstractPurpose:Tertiary lymphoid structures (TLS) are associated with improved survival and enhanced response to anticancer immunotherapy. This study aimed to develop a CT imaging–based approach for noninvasive assessment of TLSs and immunotherapy response.Experimental Design:This study involved 3,155 patients with gastric cancer. TLSs were classified into four stages (absence, Agg, FL-I, and FL-II) according to their maturation […]
- AbstractPurpose:Cancers present significant DNA methylation changes, which arise in a stochastic manner, marked by extensive epigenetic variation, indicative of high epigenetic instability. We aimed to evaluate the utility of epigenetic instability for cell-free DNA (cfDNA)-based cancer detection.Experimental Design:Through analysis of cancer DNA methylation datasets (n = 2,084), we identified a set of 269 CpG island […]
Cancer.gov
- A series of tissue changes may be associated with an increased risk of developing aggressive breast cancer among women with benign breast disease, and poorer rates of survival among women with invasive breast cancer.
- From 2010 through 2019, the incidence of 14 cancer types rose among people under age 50. However, the incidence of 19 other cancer types has decreased among this population.
- Overall death rates from cancer declined steadily among men and women from 2001 through 2022, even during the first two years of the COVID-19 pandemic, according to the 2024 Annual Report to the Nation on the Status of Cancer.
- A new form of personalized cancer immunotherapy, known as tumor infiltrating lymphocyte (TIL) therapy, dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancers.
- A study of 85,000 older adults in the U.K. suggests that light- and moderate-to-vigorous-intensity daily physical activity can reduce cancer risk. The number of steps taken daily may be more important for cancer risk than the intensity of activity, the study shows.
JAMA Oncology – Current Issue
- In Reply We thank Xu et al for their comments on our phase 2 trial of prostate-specific membrane antigen positron emission tomography (PSMA-PET)–guided intensification of salvage radiotherapy (SRT) after radical prostatectomy, in which we observed an isotoxic improvement in failure-free survival (hazard ratio [HR], 0.46; 95% CI, 0.22-0.99; P = .04). Their comments highlight an important ongoing […]
- The mirror and I have not met for years. I find no comfort in this unfamiliar reflection.
- This cohort study compares cancer control and perioperative complications among patients after salvage focal therapy vs salvage radical prostatectomy.
- This secondary analysis of the GHSG HD21 randomized clinical trial evaluates the tolerability and impact of BrECADD vs escalated BEACOPP on health-related quality of life for patients with Hodgkin lymphoma.
- A 67-year-old man with a history of λ light-chain multiple myeloma presents with increased serum-free λ light chain levels. What is your diagnosis?
ClinicalTrials.gov – Cancer
- Conditions: NSCLC Interventions: Drug: Drug: Retlirafusp alfa; Drug: Drug: Single-agent Chemotherapy; Other: Procedure: Radical Surgery Sponsors: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting
- Conditions: Acute Myeloid Leukemia Interventions: Drug: PLM-102 Sponsors: M.D. Anderson Cancer Center Not yet recruiting
- Conditions: Adult Cancer Patients; Right Atrial Clot Interventions: Diagnostic Test: Cardiac MRI Sponsors: Memorial Sloan Kettering Cancer Center; American Heart Association Recruiting
- Conditions: Neuroblastic Tumors Sponsors: The Children's Hospital of Zhejiang University School of Medicine Active, not recruiting
- Conditions: Esophageal Cancer Sponsors: Sichuan University Completed
STAT!Ref Evidence Alerts
- J Clin Oncol. 2026 Mar 12:JCO2500570. doi: 10.1200/JCO-25-00570.
- Lancet Oncol. 2026 Mar 5:S1470-2045(26)00026-4. doi: 10.1016/S1470-2045(26)00026-4.
- J Clin Oncol. 2026 Mar 20;44(9):812-824. doi: 10.1200/JCO-25-02938. Epub 2026 Feb 25.
- JAMA Oncol. 2026 Feb 26:e260020. doi: 10.1001/jamaoncol.2026.0020.
- J Clin Oncol. 2026 Jan 28:JCO2501546. doi: 10.1200/JCO-25-01546.
*For providers of Salinas Valley Health, if you need access to any particular article referred to in these news feeds, please email Library@SalinasValleyHealth.com